EAS Journal of Pharmacy and Pharmacology
Abbreviated Key Title: EAS J Pharm Pharmacol
ISSN: 2663-0990 (Print) & ISSN: 2663-6719 (Online)
Published By East African Scholars Publisher, Kenya

OPEN ACCESS

Volume-5 | Issue-5 | Sep-Oct- 2023 | DOI: 10.36349/easjpp.2023.v05i05.002

Review Article

A Comprehensive Review on Multiple Sclerosis

S. Jayashree[1], B. Senthilnathan[2*], M. Parameshwari[3], G. Karthikeyan[4], Pavithra S[5]

[1]Department of Pharmacology, Sri Venkateswaraa University, College of Pharmacy, 51, GNT Road, Nallur, Near Redhills Toll Plaza, Chennai-67, India
[2]Professor and Head, Department of Pharmaceutics, Sri Venkateswaraa University, College of Pharmacy, 51, GNT Road, Nallur, Near Redhills Toll Plaza, Chennai-67, India
[3]Department of Pharmaceutical Chemistry, Sri Venkateswaraa University, College of Pharmacy, 51, GNT Road, Nallur, Near Redhills Toll Plaza, Chennai-67, India
[4]Department of Pharmaceutical Analysis, Sri Venkateswaraa University, College of Pharmacy, 51, GNT Road, Nallur, Near Redhills Toll Plaza, Chennai-67, India
[5]Department of Pharmacy Practice, Sri Venkateswaraa University, College of Pharmacy, 51, GNT Road, Nallur, Near Redhills Toll Plaza, Chennai-67, India

Article History
Received: 01.08.2023
Accepted: 08.09.2023
Published: 12.09.2023

Journal homepage:
https://www.easpublisher.com

Quick Response Code

Abstract: Multiple Sclerosis is an extremely frequent non-traumatic debilitating illness affecting youngsters. Multiple Sclerosis is becoming more common across the globe, as is the disease's economic effect. The fundamental etiology of Multiple Sclerosis plus the processes causing this rise remain unknown, yet complicated interactions between genes and the environment virtually definitely play an important part. The major source of injury in MS is swelling of the brain and spinal cord. The exact ingredients that cause this type of inflammation are unclear. According to research, environmental, genetic, and viral causes may all have a role in the onset of MS. MS statistics suggests that reduced blood vitamin D levels, cigarette smoking, obesity in kids, and Epstein-Barr virus infection all have a role in disease progression. Because of advancements in diagnostic procedures and standards, patients with MS can now be identified at a younger age. Along with this, the quantity, effectiveness, and danger of MS therapies have risen tremendously. The prospect of a 'pre-symptomatic MS' diagnosis, which might lead to the investigation of possible preventative therapies. MS epidemiological studies, probable aetiological variables, and pathogenesis are all reviewed throughout this detailed study prior proceeding on to therapeutic elements of MS diagnostic and therapy. Recent encouraging investigations of condition-modifying medications in progressive form of MS offer persons alongside severe MS the hope of slowing the progression of the disease while keeping residual functioning. It turns out that drugs appear to work at several stages of the illness's progression puts challenge on the traditional two-stage model of MS's inherent course.

Keywords: Non-traumatic, Inflammation, Types, Multiple sclerosis, Neurodegeneration Management.

INTRODUCTION

MS is an extremely prevalent non-traumatic debilitating illness affecting young individuals [1]. MS is becoming a growing problem in nations that are both developed and developing [2], The fundamental etiology of that is unknown. MS is a complicated illness multiple genes, furthermore to various well-defined factors related to the environment, such as a deficiency in Exposure with sunlight that contains vitamin D or damaging ultraviolet B rays (UVB), Epstein-Barr virus (EBV), being overweight, and tobacco are all causes for the condition [3]. In the past, the condition multiple sclerosis (MS) had been defined as an organ-specific T-cell mediated autoimmune disease. The scientific success of B-cell specific therapy, upon the contrary together, brings the conventional T-cell autoimmune orthodoxy into doubt [4]. It had been formerly assumed that it was a two stages sickness, with acute inflammation causing relapsing-remitting symptoms followed by

***Corresponding Author:** B. Senthilnathan
Professor and Head, Department of Pharmaceutics, Sri Venkateswaraa University, College of Pharmacy, 51, GNT Road, Nallur, Near Redhills Toll Plaza, Chennai-67, India

neurodegeneration causing non-relapsing symptoms, i.e. secondary and primary Multiple sclerosis [5, 6]. The development of more potent biological drugs and a targeted approach to managing MS, namely managing to an area No evident advancement of the disease (NEDA) is changing the longer-term outcome for people with MS (pwMS). More severe immune reconstitution treatment, resulting in some instances of pwMS achieving over time remission, could bring a conclusion to the illness for just a few percent of pwMS [7]. Recent encouraging investigations of condition-modifying medications in advanced forms of MS provide individuals with worsening MS the hope of slowing the progression of the disease while maintaining residual performance [8]. It turns out that drugs seem to be effective at several stages of the disease's development puts into question the traditional two-stage model of MS's normal course [9].

Aetiology

The root cause of MS is undetermined; nevertheless, this may not be entirely true. EBV, UVB, cigarette smoking, as well as vitamin D, in conjunction alongside a person's family history, all play vital parts in the causative path that leads to MS formation [10] studies generally show that MS is caused by environmental contact [11].

Being really EBV negative safeguards against the development of MS [12, 13]. A significant EBV infection (i.e. infectious mononucleosis) increases the risk of developing MS [14]. The scientific proof for how EBV raises the risk of MS is mixed; DNA replication has long been an accepted notion [15]. EBV-induced B-cell immortalizing and/or conversion has lately been believed to have a significant role in the onset of disease [16]. Multiple sclerosis, or MS, is becoming a more widespread condition. The incidence of MS rises with latitude; however, in Norway and the United States, where it has been researched, this gradient is reducing [17]. The latitudinal variation in the incidence of MS is significantly associated with UVB radiation, which improves epidermal Vitamin D (VD) synthesis. Low (VD) levels, reduced (VD) consumption, less outdoor exercise, and higher MS sensitivity linked with genetic variations generating low (VD) values all have linked as part of the MS causative pathways [18].

The condition is more frequent among women, although this has rarely been the case. In early 1900s case series, the gender balance was about equal. Since that time, the sex ratio has progressively increased, and it currently stands roughly 3:1 (F:M) in the majority of industrialized nations [19]. Nicotine use, which increases the likelihood of developing MS by around 50%, could be responsible for as much as forty percent of the greater incidence of MS in women [20]. Before the outbreak of World War II, few women smoked; nevertheless, the percentage of women who inhaled rapidly increased after the conflict ended, paralleling the rising frequency of male smoking. Since organic solvents that are and cigarettes employed in smoking [21, 22], but not consumed cigarettes or sniff powder, have been found to be associated to MS, it was postulated that these elements cause post-translational alterations via antigenic dispersion in the respiratory tract [23].

Types of multiple sclerosis

a) Relapsing/Remitting Multiple Sclerosis (RRMS)

The most prevalent kind, accounting for around 85% of cases. Characterized by separate assaults that progress over hours to weeks resulting in a healing process that lasts the weeks to months. The individual's neurological condition does not deteriorate during bouts.

b) Secondary Progressive Multiple Sclerosis (SPMS)

Characterized by early recurrence accompanied by slow cognitive degeneration unrelated to acute attack.

c) Primary Progressive Multiple Sclerosis (PPMS)

From the outset of the disease, there is a continuous reduction in functional ability. There have never been any relapses.

d) Progressive Relapsing Multiple Sclerosis (PRMS)

Characterized by gradual functional decrease from the beginning of the illness, with subsequently severe attacks. PRMS and PPMS can't be separated until relapses occur [24].

Pathophysiology

The major source of injury in MS is swelling of the brain and spinal cord. The exact ingredients that cause this type of inflammation are unclear. According to research, environmental, genetic, and viral causes may all have a role in the onset of MS. Numerous immunologic research has been conducted on an experimental autoimmune disorders encephalomyelitis (EAE) model used for human MS. Based on this hypothesis and human findings of MS, the functions of many immune pathways implicated in MS have been investigated. To comprehend all of this, it is necessary to initially comprehend certain fundamental aspects of the immune system's role in MS. To comprehend these routes, it's necessary to initially comprehend certain fundamental aspects of the body's immune system in MS. Although the research of EAE has taught us a lot regarding the immune system as a whole, we need to keep mindful of our shortage of knowledge of the distinctions among EAE with MS, in addition to the multifaceted nature of MS (and presumably multiple immunological subtypes of MS) while analyzing behavioral and toxicological data [25]. There are actually two distinct types of immunological responses. These were two types of immunological responses: intrinsic and adaptable. The natural Antimicrobial compounds target certain receptors, primarily toll-related receptors (TLRs) in the immune system. Pathogenic-associated chemicals which are distinct to particular disease groups activate particular types of TLR. The association of these substances to TLRs, or causes the generation of cytokine.

As dendritic cells grow, they begin to divide $CD4^+$ T cells in order and separate either among Th1, Th2, or Th17 phenotypes. Inflammation is enhanced when T cells develop to a Th1 phenotype. Recent research in themodulation on the adaptive immunity response [26]. The intrinsic mechanism influences the effector properties of T and B cells, which has an impact throughout the beginning and development of MS. Dendritic cell populations (DCs), for instance, develop semi-mature if triggered by TLRs and prompt T cells that are regulatory to generate suppressive mediators that include IL-10. or TGF [27]. As their numbers grow, they begin to divide $CD4^+$ T cells in order to undergo division into either Th1, Th2, or Th17 phenotypes. Inflammation is enhanced if T cells develop to a Th1 subtype. The latest study in the EAE paradigm indicates that the substance glatiramer acetate could stimulate type II monocytes, also that boost Th2 cell generation and the formation of regulatory T cells, reducing inflammation [28].

Antigen presenting cells (APCs) trigger the immune system's response by delivering a particular antigen to lymphocytes called T lymphocytes. Cells such as B cells, dendritic cell-like cells, microglia, and macrophage are examples of cells that present antigens. The contact among the APC with the T cell is critical in initiating the immune system's response that is adaptive. APCs can stimulate various types of T lymphocytes, notably $CD4^+$ and $CD8^+$ phenotypes. Th1, Th2, and Th17 cells were $CD4^+$ effector lymphocytes that become polarized in reaction to particular interleukins. The functional T cell types create particular cytokines after being polarized to Th1, Th2, or Th17. Th1 cells release cytokines that promote inflammation like interferongamma, while Th2 cells, on the other hand, release anti-inflammatory substances including IL-4 and IL-13. Th17 constitutes a recently identified $CD4^+$T cell subgroup which secretes IL-17, IL-21, IL-22, and IL-26. Th17 cells, which function like Th1 cells, induce inflammatory in MS. IL-17 receptors have been found in both chronic as well as acute MS lesions. Furthermore, investigations with IL-17 defective animals demonstrate that the clinical impact is reduced [29]. Upon being stimulated in the peripheral, Th1 and Th17 cells move to the brain's nerve cells. Demyelination that occurs later Axonal loss is then seen [26]. Yet another $CD4^+$ T cell subtype implicated in the pathophysiology of MS is regulating T lymphocytes. T regulatory (T reg) cells are responsible for regulating functional Th1, Th2, and Th17 cells. The total amount of T reg cells among MS individuals as well as controls is the same, but those who have the condition have impaired T reg functioning [30]. FN improves the function of $CD4^+$ regulatory T cells [31]. A separate study found that the compound glatiramer acetate improves regulatory T cell activity by boosting the proliferation of naive $CD4^+$ $CD25^+$ Fox $P3^+CD31^+$ T cells [32]. Aside from the role of $CD4^+$ T cells being involved in MS pathology, investigations have demonstrated that $CD8^+$ T cell populations are found in lesions associated with MS and may play an advisory function in disease development. $CD8^+$ cells restrict $CD4^+$ T cell growth by secreting perforin, which is cytotoxic to $CD4^+$ T cells and causes their deactivation. Furthermore, $CD8^+$ lymphocytes destroy glial cells, exposing axons [27]. Furthermore, $CD8^+$ T lymphocytes transect axons, increase blood vessel permeability, and induce oligodendrocyte death. All of these phenomena can be observed in MS lesions. B cells and their products, in along with T cells, play a role in the pathogenesis of MS. It is well known that B lymphocytes develop into cells called plasma that produce antibody. Oligoclonal bands are a sign of such antibodies that are polyclonal in the spinal fluid of MS patients. The intended target for these antibodies is unknown at this time. B cell types have been shown to generate both proinflammatory (lymphotoxin, TNF-alpha generated by recollection B cells) and anti-inflammatory in nature (IL-10) mediators (made by naive B cells) cytokines [33]. CD20, the biological target of the monoclonal antibody rituximab, appears throughout B cell maturation but not on the plasma cells. In addition, demonstrated the presence of B cell follicles in the brains of MS patients. CD20 is expressed in these follicle [34]. The loss of $CD20^+$ B cells following rituximab administration has been reported in research that enhance B cell antigen-presenting capabilities an antigen nonspecific way [35].

Genetic factor

The pathophysiology of multiple sclerosis exposure is influenced by genes. Family and twin studies have revealed a 40-fold spike in vulnerability amongst family members of MS patients, implying a genetic basis. MS vulnerability is believed to be related to a particular HLA locus in chromosomes 6p21, that includes the DR antigen. In risky populations, of north european a HLA-DRB1*1501-DQB1*0602 haplotype (DR2) has been frequently established. The chromosome 10p15, 5p13, and 1p36 are also susceptible loci [36].

Environmental factors

It is believed that environmental variables, such as contact with germs and vitamin D from sunlight, explain for the shifting risk of MS when a person moves from one risk location to a different one around the age of 15 [37]. Kids and teens with MS have been the subjects of numerous recent research that point to an infectious origin. Human herpes virus type 6, Epstein-Barr virus, and mycoplasma pneumoniae are a few of the pathogens that may be involved [38]. It is hypothesized that mimicry of molecules could be one route for infections to cause MS. The infections may have peptides that directly resemble the amino acids in myelin.It is also evident that typical viral illnesses such upper respiratory tract infections and bacteria urinary tract infections can cause MS relapses.

A persistent inflammation neurological & degenerative condition Multiple sclerosis, also known as spinal cord, and brain (CNS) illness also known as MS, is a particularly common cause of long-term impairment in young people. The average age at onset is between 20 and 50, with peaks at 29 and 30 for men and women respectively. About two times as many women as males experience symptoms. It is still largely unresolved what happens first to cause the condition. The development of MS is influenced by intricate hereditary and environmental relationships [39].

Age

A later menopause age is associated with an increased chance of MS in women, according to a population-based research. In contrast to previous study involving a limited number of female patients, having relapse remitting MS there wasn't no association among age at menopause and age at illness beginning. Age at adolescence had no impact on the likelihood of developing MS in men [40]. An older age at menopause has lately been connected to a lower probability of progressing onset MS patients reaching the EDSS 6 milestone, which requires assistance for walking 100 meters [41, 42].

Clinical Features

The predominant clinical manifestation of the disease is illness linked with a sudden onset of a complete transverse myelitis, which are generally sensory complaints that suggest dorsolateral cord activation [41]. Whichever is the size of the lesion, complaints could be either unilateral or bilateral, regardless of the surface of your lesion, and most usually happens in the cervical cord in multiple sclerosis (ms). Cognitive operation, including bladder and bowel function, could be affected. Sudden full transverse myelitis accompanied with paraplegia is uncommon for multiple myeloma and should encourage further investigation into other conditions that include neuromyelitis optica spectrum disorders (NMOSD). Sudden myelitis caused by multiple sclerosis (MS) normally develops over a few weeks and continues to heal on its own after a few days have passed. The vast majority of individuals with an image of the brain indicative of multiple sclerosis associated with a form of acute transversal myelitis will fulfill numerous disease diagnostic requirements in a few years [42]. Beginning with a more gradual start should raise the possibility of PPMS, which manifests as a gradual myelopathy in around 80% of patients [43]. Motor symptoms like fragility, stiffness, and walking problems prevail over sensory signs in PPMS. According to the rest of the clinical scenario, compressible illness, toxic-metabolic triggers like vitamin B12 or copper deficiency, getting sick like as human T-cell lymphotropic the virus, cancer, or an underlying family history so when hereditary spastic paraparesis [41, 44].

Optic Neuritis

Optic neuritis, a condition caused by intrinsic multiple sclerosis usually manifests as an abrupt, unilateral, painful reduction in vision that peaks in a few days and tends to subside in a matter of weeks [45]. A hyper acute appearance ought to indicate the possibility of a vascular process, while an additional hidden presenting ought to improve the possibility of an infiltrative chaos such as neurosarcoidosis, toxic metabolic procedure like as a lack of B12, or para neoplastic syndrome, nevertheless the PPMS may occasionally present with slowly worsening vision because of progressive optic neuropathy [43]. Concurrent bilaterality is feasible but unusual and should arouse concern for diseases like NMOSD, neuro sarcoidosis, or Leber's inherited optic neuropathy (LHON), particularly when a history of these conditions in the family exists. Pain during movement of the eyes is common in numerous sclerosis-related optic neuritis.

Cerebellar Syndrome

Diplopia owing to internuclear ophthalmoplegia, that can be bilaterally, is the most frequent brainstem manifestation of multiple sclerosis, which while diplopia can also be caused by a sixth nerve dysfunction. Facial stiffness or lack of feeling may follow or happen independently of aberrant eye movements. A lesion somewhere in the vestibular networks can cause vertigo, while a cerebellar stroke can cause ataxia [46]. A chronic cerebellar or brainstem condition, defined primarily by steadily deteriorating ataxia, affects around 15% of individuals having PPMS [46].

Cognitive impairment

Cognitive decline is widespread across all phenotypes of multiple sclerosis that develops at the beginning of the illness, albeit it's far more apparent in progressing then recurrent multiple sclerosis. Cognitive grievances are frequently associated with additional signs of the illness and can help harden the diagnosis; nevertheless, due to there general the natural world and not having an association in an identifiable acute central nervous system lesion (a minimum of with present-day imaging techniques), cognitive signs by itself without concentrated neurological signs are not usually useful discrimination in establishing a diagnosis for RRMS. A recent study demonstrated in a small sample of Italian participants. PPMS can appear primarily cognitive loss without evident concurrent focal neurological complaints and indications [47].

Diagnosis

MS is clinically defined by distinct bouts of neurologic impairment ("attacks," "exacerbations," or "relapses"). The sort and severity of signs caused by these periods vary greatly among individuals and are determined by the place of neurologic activation. Numbness, sensations of ting vulnerability, blurred vision, gait damage, incoordination, instability, and

urinary tract problems are typical symptoms. Individuals exhibit rather steady neurological function during the intervals these episodes, at least throughout the paying stages of the disease. Nonetheless, lingering symptoms may continue, and many patients report weariness or discomfort with heat between bouts. Several individuals that begin with relapsing-remitting multiple sclerosis (RRMS) advance throughout a number of years to centuries to primary progressive characteristics of the condition, whereby sufferers experience a gradual loss of functioning and a development of neurologic impairment. Regardless of with any possible sudden attacks. This can be particularly true to individuals who have not been treated [48].

Clinical expertise plays a significant role in MS identification [49]. The medical classification of the condition is based on the occurrence of signs and symptoms due to white matter lesions on MR imaging that are propagated in time (ie, the disease obviously) and time (ie, the affected areas in the CNS), in addition to the ruling out of other illnesses that may look like MS [50, 51]. There's no one testing facility that can diagnose MS [52]. The diagnostic techniques necessary to identify MS and rule out other diseases, alongside to a comprehensive historical and physical check up, includes MRI, CSF evaluation, and activated potential testing. CSF examination reveals higher immunoglobulin concentrations as well as two or more oligoclonal bands.The elimination of alternative explanations is another key component of MS diagnosis. The number of clinical and radiological disorders that resemble MS is wide; nevertheless, in the clinical setting, there are only a few illnesses that really mirror MS on both areas. In MS, clinical presentation and neurologic localization must guide differential diagnosis [49]. Nonspecific neurological signs (for example, migraine headaches, useful neurologic illnesses, fibromyalgia, as well as smaller vessel an ischemic illness alone or in combo), other demyelinating problems (for example, neuromyelitisoptica, accidental myelitis transverse, and severe disseminated encephalomyelitis), systematic inflammation in CNS symptoms (for example, sarcoidosis, CNS vasculitis/vasculopathy, HIV [51].

Management of disease

People with MS might have severe impairment and low levels life satisfaction (QoL) for a long time. The condition's expenses, which include medical care, social care, and loss of productivity, are considerable and are related to illness severity. MS mostly impacts young individuals, and sufferers struggle for the rest of their lives [53]. A MS diagnosis has significant social and psychological effects. A variety of MS symptoms, such as cognitive impairment, mental illnesses, pain, and tiredness, are commonly overlooked, despite the fact that they frequently serve as substantial contributors to disability. The illness usually strikes during a patient's most productive years. Initially diagnosed individuals might be taken aback by the fact that they have an ongoing illness that is unexpected in its progression, progressive in nature not curable, and has a detrimental effect on their working [54]. Individuals might be faced with concerns such as diminished mobility, disability, and interruptions in school, job, sexuality and familial functioning properly, relationships, and regular daily tasks. Individuals can experience weariness, discomfort, impaired vision, weakness, urinary and/or gastrointestinal problems, and reduced mobility. They might exhibit poor cognition, sadness, a lack of social contact, or an increasing dependency on other [55]. In terms of job opportunities, one research discovered that the prevalence among unemployed individuals might reach 75% after a ten-year period after an MS diagnosism [56]. The gloomy outlook and uncertainty of daily health in RRMS, as well as the negative effects of medicines, have a significant impact on QoL [57].

CONCLUSION

MS is a persistent, autoimmune illness which has a significant mental, physical, and social effect on individuals. Its incidence is growing and women are more inclined to contract it. The latitudinal difference in MS prevalence seems to be flattening across European and the United States. Environment and gene-related factors are thought to play a role in the early stages of MS. Although some clinical markers are common of MS, the disease presentation varies greatly in terms of symptoms, speed, and development.

REFERENCES

1. Kobelt, G., Thompson, A., Berg, J., Gannedahl, M., Eriksson, J., MSCOI Study Group, & European Multiple Sclerosis Platform (2017). New insights into the burden and costs of multiple sclerosis in Europe. *Multiple sclerosis (Houndmills, Basingstoke,England)*, *23*(8), 1123–1136. https://doi.org/10.1177/1352458517694432
2. Browne, P., Chandraratna, D., Angood, C., Tremlett, H., Baker, C., Taylor, B. V., & Thompson, A. J. (2014). Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. *Neurology*, *83*(11), 1022–1024. https://doi.org/10.1212/WNL.0000000000000768
3. Ascherio A. (2013). Environmental factors in multiple sclerosis. *Expert review of neurotherapeutics*, *13*(12 Suppl), 3–9. https://doi.org/10.1586/14737175.2013.865866
4. Greenfield, A. L., & Hauser, S. L. (2018). B-cell Therapy for Multiple Sclerosis: Entering an era. *Annals of neurology*, *83*(1), 13–26. https://doi.org/10.1002/ana.25119
5. Leray, E., Yaouanq, J., Le Page, E., Coustans, M., Laplaud, D., Oger, J., &Edan, G. (2010). Evidence for a two-stage disability progression in multiple sclerosis. *Brain: a journal of neurology*, *133*(Pt 7), 1900–1913. https://doi.org/10.1093/brain/awq076
6. Coles, A. J., Cox, A., Le Page, E., Jones, J., Trip, S. A., Deans, J., Seaman, S., Miller, D. H., Hale, G.,

Waldmann, H., &Compston, D. A. (2006). The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. *Journal of neurology*, *253*(1), 98–108. https://doi.org/10.1007/s00415-005-0934-5

7. Muraro, P. A., Pasquini, M., Atkins, H. L., Bowen, J. D., Farge, D., Fassas, A., ...&Saccardi, R. (2017). Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. *JAMA neurology*, *74*(4), 459-469.
8. Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., ...&Wolinsky, J. S. (2017). Ocrelizumab versus placebo in primary progressive multiple sclerosis. *New England Journal of Medicine*, *376*(3), 209-220.
9. Giovannoni, G., Cutter, G., Sormani, M. P., Belachew, S., Hyde, R., Koendgen, H., ...&Schmierer, K. (2017). Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. *Multiple sclerosis and related disorders*, *12*, 70-78.
10. Ramagopalan, S. V., Dobson, R., Meier, U. C., &Giovannoni, G. (2010). Multiple sclerosis: risk factors, prodromes, and potential causal pathways. *The Lancet Neurology*, *9*(7), 727-739.
11. Kurtzke J. F. (2013). Epidemiology in multiple sclerosis: a pilgrim's progress. *Brain: a journal of neurology*, *136*(Pt 9), 2904–2917. https://doi.org/10.1093/brain/awt220
12. Ascherio, A., &Munger, K. L. (2007). Environmental risk factors for multiple sclerosis. Part I: the role of infection. *Annals of neurology*, *61*(4), 288–299. https://doi.org/10.1002/ana.21117
13. Pakpoor, J., Disanto, G., Gerber, J. E., Dobson, R., Meier, U. C., Giovannoni, G., &Ramagopalan, S. V. (2013). The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis. *Multiple sclerosis (Houndmills, Basingstoke, England)*, *19*(2), 162–166. https://doi.org/10.1177/1352458512449682
14. Handel, A. E., Williamson, A. J., Disanto, G., Handunnetthi, L., Giovannoni, G., &Ramagopalan, S. V. (2010). An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. *PloS one*, *5*(9), e12496. https://doi.org/10.1371/journal.pone.0012496
15. Lang, H. L., Jacobsen, H., Ikemizu, S., Andersson, C., Harlos, K., Madsen, L., ...& Fugger, L. (2002). A functional and structural basis for TCR cross-reactivity in multiple sclerosis. *Nature immunology*, *3*(10), 940-943.
16. Tracy, S. I., Kakalacheva, K., Lünemann, J. D., Luzuriaga, K., Middeldorp, J., & Thorley-Lawson, D. A. (2012). Persistence of Epstein-Barr virus in self-reactive memory B cells. *Journal of virology*, *86*(22), 12330–12340. https://doi.org/10.1128/JVI.01699-12
17. Koch-Henriksen, N., &Sørensen, P. S. (2010). The changing demographic pattern of multiple sclerosis epidemiology. *The Lancet. Neurology*, *9*(5), 520–532. https://doi.org/10.1016/S1474-4422(10)70064-8
18. Sintzel, M. B., Rametta, M., &Reder, A. T. (2018). Vitamin D and Multiple Sclerosis: A Comprehensive Review. *Neurology and therapy*, *7*(1), 59–85. https://doi.org/10.1007/s40120-017-0086-4
19. Orton, S. M., Herrera, B. M., Yee, I. M., Valdar, W., Ramagopalan, S. V., Sadovnick, A. D., Ebers, G. C., & Canadian Collaborative Study Group (2006). Sex ratio of multiple sclerosis in Canada: a longitudinal study. *The Lancet. Neurology*, *5*(11), 932–936. https://doi.org/10.1016/S1474-4422(06)70581-6
20. Palacios, N., Alonso, A., Brønnum-Hansen, H., &Ascherio, A. (2011). Smoking and increased risk of multiple sclerosis: parallel trends in the sex ratio reinforce the evidence. *Annals of epidemiology*, *21*(7), 536–542. https://doi.org/10.1016/j.annepidem.2011.03.001
21. Napier, M. D., Poole, C., Satten, G. A., Ashley-Koch, A., Marrie, R. A., & Williamson, D. M. (2016). Heavy metals, organic solvents, and multiple sclerosis: An exploratory look at gene-environment interactions. *Archives of environmental & occupational health*, *71*(1), 26–34. https://doi.org/10.1080/19338244.2014.937381
22. Handel, A. E., Williamson, A. J., Disanto, G., Dobson, R., Giovannoni, G., &Ramagopalan, S. V. (2011). Smoking and multiple sclerosis: an updated meta-analysis. *PloS one*, *6*(1), e16149. https://doi.org/10.1371/journal.pone.0016149
23. Hedström, A. K., Bäärnhielm, M., Olsson, T., &Alfredsson, L. (2009). Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. *Neurology*, *73*(9), 696–701. https://doi.org/10.1212/WNL.0b013e3181b59c40
24. Loma, I., &Heyman, R. (2011). Multiple sclerosis: pathogenesis and treatment. *Current neuropharmacology*, *9*(3), 409–416. https://doi.org/10.2174/157015911796557911
25. Codarri, L., Fontana, A., &Becher, B. (2010). Cytokine networks in multiple sclerosis: lost in translation. *Current opinion in neurology*, *23*(3), 205–211. https://doi.org/10.1097/WCO.0b013e3283391feb
26. Gandhi, R., Laroni, A., & Weiner, H. L. (2010). Role of the innate immune system in the pathogenesis of multiple sclerosis. *Journal of neuroimmunology*, *221*(1-2), 7–14. https://doi.org/10.1016/j.jneuroim.2009.10.015
27. Kasper, L. H., & Shoemaker, J. (2010). Multiple sclerosis immunology: The healthy immune system vs the MS immune system. *Neurology*, *74 Suppl 1*, S2–S8. https://doi.org/10.1212/WNL.0b013e3181c97c8f
28. Weber, M. S., Prod'homme, T., Youssef, S., Dunn, S. E., Rundle, C. D., Lee, L., Patarroyo, J. C., Stüve,

O., Sobel, R. A., Steinman, L., &Zamvil, S. S. (2007). Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. *Nature medicine*, *13*(8), 935–943. https://doi.org/10.1038/nm1620

29. Komiyama, Y., Nakae, S., Matsuki, T., Nambu, A., Ishigame, H., Kakuta, S., Sudo, K., &Iwakura, Y. (2006). IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. *Journal of immunology (Baltimore, Md. : 1950)*, *177*(1), 566–573. https://doi.org/10.4049/jimmunol.177.1.566
30. Haas, J., Hug, A., Viehöver, A., Fritzsching, B., Falk, C. S., Filser, A., Vetter, T., Milkova, L., Korporal, M., Fritz, B., Storch-Hagenlocher, B., Krammer, P. H., Suri-Payer, E., &Wildemann, B. (2005). Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. *European journal of immunology*, *35*(11), 3343–3352. https://doi.org/10.1002/eji.200526065
31. de Andrés, C., Aristimuño, C., de Las Heras, V., Martínez-Ginés, M. L., Bartolomé, M., Arroyo, R., Navarro, J., Giménez-Roldán, S., Fernández-Cruz, E., & Sánchez-Ramón, S. (2007). Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis. *Journal of neuroimmunology*, *182*(1-2), 204–211. https://doi.org/10.1016/j.jneuroim.2006.09.012
32. Haas, J., Korporal, M., Balint, B., Fritzsching, B., Schwarz, A., &Wildemann, B. (2009). Glatiramer acetate improves regulatory T-cell function by expansion of naive CD4(+)CD25(+)FOXP3(+)CD31(+) T-cells in patients with multiple sclerosis. *Journal of neuroimmunology*, *216*(1-2), 113–117. https://doi.org/10.1016/j.jneuroim.2009.06.011
33. Duddy, M., Niino, M., Adatia, F., Hebert, S., Freedman, M., Atkins, H., Kim, H. J., & Bar-Or, A. (2007). Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. *Journal of immunology (Baltimore, Md. : 1950)*, *178*(10), 6092–6099. https://doi.org/10.4049/jimmunol.178.10.6092
34. Magliozzi, R., Howell, O., Vora, A., Serafini, B., Nicholas, R., Puopolo, M., Reynolds, R., &Aloisi, F. (2007). Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. *Brain: a journal of neurology*, *130*(Pt 4), 1089–1104. https://doi.org/10.1093/brain/awm038
35. Hawker K. (2009). B cells as a target of immune modulation. *Annals of Indian Academy of Neurology*, *12*(4), 221–225. https://doi.org/10.4103/0972-2327.58275
36. Barcellos, L. F., Oksenberg, J. R., Begovich, A. B., Martin, E. R., Schmidt, S., Vittinghoff, E., Goodin, D. S., Pelletier, D., Lincoln, R. R., Bucher, P., Swerdlin, A., Pericak-Vance, M. A., Haines, J. L., Hauser, S. L., & Multiple Sclerosis Genetics Group (2003). HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. *American journal of human genetics*, *72*(3), 710–716. https://doi.org/10.1086/367781
37. Milo, R., &Kahana, E. (2010). Multiple sclerosis: geoepidemiology, genetics and the environment. *Autoimmunity reviews*, *9*(5), A387–A394. https://doi.org/10.1016/j.autrev.2009.11.010
38. Fujinami, R. S., von Herrath, M. G., Christen, U., &Whitton, J. L. (2006). Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. *Clinical microbiology reviews*, *19*(1), 80–94. https://doi.org/10.1128/CMR.19.1.80-94.2006
39. D'hooghe, M. B., D'Hooghe, T., & De Keyser, J. (2013). Female gender and reproductive factors affecting risk, relapses and progression in multiple sclerosis. *Gynecologic and obstetric investigation*, *75*(2), 73–84. https://doi.org/10.1159/000346319
40. Ramagopalan, S. V., Valdar, W., Criscuoli, M., DeLuca, G. C., Dyment, D. A., Orton, S. M., ...& Canadian Collaborative Study Group. (2009). Age of puberty and the risk of multiple sclerosis: a population based study. *European journal of neurology*, *16*(3), 342-347.
41. Cree B. A. (2014). Acute inflammatory myelopathies. *Handbook of clinical neurology*, *122*, 613–667. https://doi.org/10.1016/B978-0-444-52001-2.00027-3
42. Bourre, B., Zéphir, H., Ongagna, J. C., Cordonnier, C., Collongues, N., Debette, S., Fleury, M. C., Outteryck, O., Hannequin, D., Vermersch, P., & de Seze, J. (2012). Long-term follow-up of acute partial transverse myelitis. *Archives of neurology*, *69*(3), 357–362. https://doi.org/10.1001/archneurol.2011.949
43. Miller, D. H., & Leary, S. M. (2007). Primary-progressive multiple sclerosis. *The Lancet. Neurology*, *6*(10), 903–912. https://doi.org/10.1016/S1474-4422(07)70243-0
44. Weisfeld-Adams, J. D., Katz Sand, I. B., Honce, J. M., & Lublin, F. D. (2015). Differential diagnosis of Mendelian and mitochondrial disorders in patients with suspected multiple sclerosis. *Brain: a journal of neurology*, *138*(Pt 3), 517–539. https://doi.org/10.1093/brain/awu397
45. Corbett, J. J., Thompson, H. S., Musser, C., Kardon, R. H., Farrell, T., Graff-Redford, N. R., ...& Optic Neuritis Study Group. (1991). The clinical profile of optic neuritis. Experience of the optic neuritis treatment trial. Optic Neuritis Study Group. *Archives of ophthalmology (1960)*, *109*(12), 1673-1678.
46. Miller, D. H., Chard, D. T., &Ciccarelli, O. (2012). Clinically isolated syndromes. *The Lancet.*

Neurology, *11*(2), 157–169. https://doi.org/10.1016/S1474-4422(11)70274-5

47. Calabrese, M., Gajofatto, A., Gobbin, F., Turri, G., Richelli, S., Matinella, A., ...& Monaco, S. (2015). Late-onset multiple sclerosis presenting with cognitive dysfunction and severe cortical/infratentorial atrophy. *Multiple Sclerosis Journal*, *21*(5), 580-589.
48. Gelfand J. M. (2014). Multiple sclerosis: diagnosis, differential diagnosis, and clinical presentation. *Handbook of clinical neurology*, *122*, 269–290. https://doi.org/10.1016/B978-0-444-52001-2.00011-X
49. Solomon, A. J., &Weinshenker, B. G. (2013). Misdiagnosis of multiple sclerosis: frequency, causes, effects, and prevention. *Current neurology and neuroscience reports*, *13*(12), 403. https://doi.org/10.1007/s11910-013-0403-y
50. Hunter S. F. (2016). Overview and diagnosis of multiple sclerosis. *The American journal of managed care*, *22*(6 Suppl), s141–s150.
51. Miller, D. H., Weinshenker, B. G., Filippi, M., Banwell, B. L., Cohen, J. A., Freedman, M. S., Galetta, S. L., Hutchinson, M., Johnson, R. T., Kappos, L., Kira, J., Lublin, F. D., McFarland, H. F., Montalban, X., Panitch, H., Richert, J. R., Reingold, S. C., &Polman, C. H. (2008). Differential diagnosis of suspected multiple sclerosis: a consensus approach. *Multiple sclerosis (Houndmills, Basingstoke, England)*, *14*(9), 1157–1174. https://doi.org/10.1177/1352458508096878
52. Digre, K. B. (2002). McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. *Journal Of Neuro-Ophthalmology*, *22*(2), 143.
53. Melcon, M. O., Correale, J., & Melcon, C. M. (2014). Is it time for a new global classification of multiple sclerosis? *Journal of the neurological sciences*, *344*(1-2), 171–181. https://doi.org/10.1016/j.jns.2014.06.051
54. Cioncoloni, D., Innocenti, I., Bartalini, S., Santarnecchi, E., Rossi, S., Rossi, A., &Ulivelli, M. (2014). Individual factors enhance poor health-related quality of life outcome in multiple sclerosis patients. Significance of predictive determinants. *Journal of the neurological sciences*, *345*(1-2), 213–219. https://doi.org/10.1016/j.jns.2014.07.050
55. Hunter, S. F. (2016). Overview and diagnosis of multiple sclerosis. *Am J Manag Care*, *22*(6 Suppl), s141-50.
56. Ford, D. V., Jones, K. H., Middleton, R. M., Lockhart-Jones, H., Maramba, I. D., Noble, G. J., ... & Lyons, R. A. (2012). The feasibility of collecting information from people with Multiple Sclerosis for the UK MS Register via a web portal: characterising a cohort of people with MS. *BMC medical informatics and decision making*, *12*(1), 1-8.
57. Pagnini, F., Bosma, C. M., Phillips, D., & Langer, E. (2014). Symptom changes in multiple sclerosis following psychological interventions: a systematic review. *BMC neurology*, *14*, 222. https://doi.org/10.1186/s12883-014-0222-z

Cite This Article: S. Jayashree, B. Senthilnathan, M. Parameshwari, G. Karthikeyan, Pavithra S (2023). A Comprehensive Review on Multiple Sclerosis. *EAS J Pharm Pharmacol*, *5*(5), 132-139.